{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:19:39Z","timestamp":1781479179130,"version":"3.54.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Natural Science Foundation of China","award":["2024J011461"],"award-info":[{"award-number":["2024J011461"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10455-1","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T03:48:36Z","timestamp":1729136916000},"page":"191-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects"],"prefix":"10.1007","volume":"30","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinv","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"13","key":"10455_CR1","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/bph.15746","volume":"179","author":"C Grossmann","year":"2022","unstructured":"Grossmann C, Almeida-Prieto B, Nolze A, Alvarez de la Rosa D (2022) Structural and molecular determinants of mineralocorticoid receptor signalling. Br J Pharmacol 179(13):3103\u20133118. https:\/\/doi.org\/10.1111\/bph.15746","journal-title":"Br J Pharmacol"},{"issue":"13","key":"10455_CR2","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179(13):3220\u20133234. https:\/\/doi.org\/10.1111\/bph.15747","journal-title":"Br J Pharmacol"},{"key":"10455_CR3","doi-asserted-by":"publisher","unstructured":"Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL (2022) Nonsteroidal mineralocorticoid receptor antagonism by finerenone-translational aspects and clinical perspectives across multiple organ systems. Int J Mol Sci 23(16).\u00a0https:\/\/doi.org\/10.3390\/ijms23169243","DOI":"10.3390\/ijms23169243"},{"issue":"11","key":"10455_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","volume":"30","author":"J Barrera-Chimal","year":"2021","unstructured":"Barrera-Chimal J, Kolkhof P, Lima-Posada I, Joachim A, Rossignol P, Jaisser F (2021) Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs 30(11):1141\u20131157. https:\/\/doi.org\/10.1080\/13543784.2021.2002844","journal-title":"Expert Opin Investig Drugs"},{"issue":"13","key":"10455_CR5","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1111\/bph.15708","volume":"179","author":"J Bauersachs","year":"2022","unstructured":"Bauersachs J, Lopez-Andres N (2022) Mineralocorticoid receptor in cardiovascular diseases-clinical trials and mechanistic insights. Br J Pharmacol 179(13):3119\u20133134. https:\/\/doi.org\/10.1111\/bph.15708","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10455_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"issue":"1","key":"10455_CR7","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L (2017) 30 Years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 234(1):T125\u2013T140. https:\/\/doi.org\/10.1530\/JOE-16-0600","journal-title":"J Endocrinol"},{"issue":"2","key":"10455_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ajh\/hpw105","volume":"30","author":"T Dudenbostel","year":"2017","unstructured":"Dudenbostel T, Calhoun DA (2017) Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens 30(2):103\u2013109. https:\/\/doi.org\/10.1093\/ajh\/hpw105","journal-title":"Am J Hypertens"},{"issue":"46","key":"10455_CR9","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"MS Kallistratos","year":"2018","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ (2018) Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des 24(46):5537\u20135541. https:\/\/doi.org\/10.2174\/1381612825666190222144359","journal-title":"Curr Pharm Des"},{"issue":"36","key":"10455_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10455_CR11","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","volume":"172","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Joseph A, Kintscher U (2021) Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy. Pharmacol Res 172:105859. https:\/\/doi.org\/10.1016\/j.phrs.2021.105859","journal-title":"Pharmacol Res"},{"issue":"23","key":"10455_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, Investigators F-D (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"6","key":"10455_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B, Investigators F-D (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145(6):437\u2013447. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"issue":"6","key":"10455_CR14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, Anker SD, Investigators F-D (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996\u20131005. https:\/\/doi.org\/10.1002\/ejhf.2469","journal-title":"Eur J Heart Fail"},{"issue":"10159","key":"10455_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD Disease","year":"2018","unstructured":"Disease GBD, Injury I, Prevalence C (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"issue":"9","key":"10455_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug BA (2020) Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 17(9):559\u2013573. https:\/\/doi.org\/10.1038\/s41569-020-0363-2","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10455_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail 22(8):1342\u20131356. https:\/\/doi.org\/10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10455_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","volume":"21","author":"NR Jones","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ (2019) Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 21(11):1306\u20131325. https:\/\/doi.org\/10.1002\/ejhf.1594","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10455_CR19","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"10455_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijcard.2015.07.038","volume":"200","author":"A Capuano","year":"2015","unstructured":"Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ (2015) Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol 200:15\u201319. https:\/\/doi.org\/10.1016\/j.ijcard.2015.07.038","journal-title":"Int J Cardiol"},{"issue":"1","key":"10455_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","volume":"22","author":"U Kintscher","year":"2023","unstructured":"Kintscher U, Edelmann F (2023) The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol 22(1):162. https:\/\/doi.org\/10.1186\/s12933-023-01899-0","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10455_CR22","doi-asserted-by":"publisher","first-page":"T23","DOI":"10.1530\/JOE-17-0060","volume":"234","author":"PJ Fuller","year":"2017","unstructured":"Fuller PJ, Yang J, Young MJ (2017) 30 Years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity. J Endocrinol 234(1):T23\u2013T34. https:\/\/doi.org\/10.1530\/JOE-17-0060","journal-title":"J Endocrinol"},{"issue":"13","key":"10455_CR23","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/bph.15719","volume":"179","author":"D Clarisse","year":"2022","unstructured":"Clarisse D, Deng L, de Bosscher K, Lother A (2022) Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor. Br J Pharmacol 179(13):3235\u20133249. https:\/\/doi.org\/10.1111\/bph.15719","journal-title":"Br J Pharmacol"},{"key":"10455_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.vh.2018.09.004","volume":"109","author":"PJ Fuller","year":"2019","unstructured":"Fuller PJ, Yang J, Young MJ (2019) Mechanisms of mineralocorticoid receptor signaling. Vitam Horm 109:37\u201368. https:\/\/doi.org\/10.1016\/bs.vh.2018.09.004","journal-title":"Vitam Horm"},{"issue":"4","key":"10455_CR25","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/00004872-198812040-00038","volume":"6","author":"PT Pearce","year":"1988","unstructured":"Pearce PT, Funder JW (1988) Steroid binding to cardiac type I receptors: in vivo studies. J Hypertens Suppl 6(4):S131-133. https:\/\/doi.org\/10.1097\/00004872-198812040-00038","journal-title":"J Hypertens Suppl"},{"issue":"6","key":"10455_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1530\/eje.0.1460789","volume":"146","author":"M Quinkler","year":"2002","unstructured":"Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V (2002) Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur J Endocrinol 146(6):789\u2013799. https:\/\/doi.org\/10.1530\/eje.0.1460789","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10455_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41371-020-0360-2","volume":"35","author":"PJ Fuller","year":"2021","unstructured":"Fuller PJ, Yao YZ, Yang J, Young MJ (2021) Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective. J Hum Hypertens 35(2):110\u2013116. https:\/\/doi.org\/10.1038\/s41371-020-0360-2","journal-title":"J Hum Hypertens"},{"issue":"11","key":"10455_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102(11):1359\u20131367. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.174235","journal-title":"Circ Res"},{"issue":"1","key":"10455_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","volume":"68","author":"F Jaisser","year":"2016","unstructured":"Jaisser F, Farman N (2016) Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 68(1):49\u201375. https:\/\/doi.org\/10.1124\/pr.115.011106","journal-title":"Pharmacol Rev"},{"key":"10455_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.steroids.2014.05.001","volume":"91","author":"V Marzolla","year":"2014","unstructured":"Marzolla V, Armani A, Feraco A, De Martino MU, Fabbri A, Rosano G, Caprio M (2014) Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids 91:46\u201353. https:\/\/doi.org\/10.1016\/j.steroids.2014.05.001","journal-title":"Steroids"},{"key":"10455_CR31","doi-asserted-by":"publisher","unstructured":"Fujii W, Shibata S (2023) Mineralocorticoid receptor antagonists for preventing chronic kidney disease progression: current evidence and future challenges. Int J Mol Sci 24(9) https:\/\/doi.org\/10.3390\/ijms24097719","DOI":"10.3390\/ijms24097719"},{"issue":"3","key":"10455_CR32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor Compr Physiol 4(3):965\u2013994. https:\/\/doi.org\/10.1002\/cphy.c130044","journal-title":"The multifaceted mineralocorticoid receptor Compr Physiol"},{"issue":"6","key":"10455_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","volume":"14","author":"UA Hawkins","year":"2012","unstructured":"Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE (2012) The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep 14(6):573\u2013580. https:\/\/doi.org\/10.1007\/s11906-012-0297-0","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10455_CR34","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/JOE-17-0009","volume":"234","author":"JJ DuPont","year":"2017","unstructured":"DuPont JJ, Jaffe IZ (2017) 30 Years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature. J Endocrinol 234(1):T67\u2013T82. https:\/\/doi.org\/10.1530\/JOE-17-0009","journal-title":"J Endocrinol"},{"issue":"1","key":"10455_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","volume":"12","author":"J Bauersachs","year":"2011","unstructured":"Bauersachs J (2011) Lother A (2022) Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl 12(1):19\u201326. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.001","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"10455_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9(8):459\u2013469. https:\/\/doi.org\/10.1038\/nrneph.2013.110","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"10455_CR37","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","volume":"120","author":"MG Usher","year":"2010","unstructured":"Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120(9):3350\u20133364. https:\/\/doi.org\/10.1172\/JCI41080","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"10455_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.mce.2003.10.047","volume":"217","author":"AE Rudolph","year":"2004","unstructured":"Rudolph AE, Rocha R, McMahon EG (2004) Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 217(1\u20132):229\u2013238. https:\/\/doi.org\/10.1016\/j.mce.2003.10.047","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10455_CR39","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1006\/jmcc.2000.1159","volume":"32","author":"JS Silvestre","year":"2000","unstructured":"Silvestre JS, Robert V, Escoubet B, Heymes C, Oubenaissa A, Desopper C, Swynghedauw B, Delcayre C (2000) Different regulation of cardiac and renal corticosteroid receptors in aldosterone-salt treated rats: effect of hypertension and glucocorticoids. J Mol Cell Cardiol 32(7):1249\u20131263. https:\/\/doi.org\/10.1006\/jmcc.2000.1159","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10455_CR40","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young M, Fullerton M, Dilley R, Funder J (1994) Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93(6):2578\u20132583. https:\/\/doi.org\/10.1172\/JCI117269","journal-title":"J Clin Invest"},{"issue":"7","key":"10455_CR41","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1210\/en.2004-0005","volume":"145","author":"M Young","year":"2004","unstructured":"Young M, Funder JW (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/salt-treated rats. Endocrinology 145(7):3153\u20133157. https:\/\/doi.org\/10.1210\/en.2004-0005","journal-title":"Endocrinology"},{"issue":"5","key":"10455_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.05981","volume":"66","author":"LA Bienvenu","year":"2015","unstructured":"Bienvenu LA, Reichelt ME, Morgan J, Fletcher EK, Bell JR, Rickard AJ, Delbridge LM, Young MJ (2015) Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult. Hypertension 66(5):970\u2013977. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05981","journal-title":"Hypertension"},{"issue":"4","key":"10455_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G, Bauersachs J (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123(4):400\u2013408. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.983023","journal-title":"Circulation"},{"issue":"6","key":"10455_CR44","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","volume":"60","author":"AJ Rickard","year":"2012","unstructured":"Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM, Young MJ (2012) Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis. Hypertension 60(6):1443\u20131450. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.203158","journal-title":"Hypertension"},{"issue":"7","key":"10455_CR45","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1210\/en.2011-2098","volume":"153","author":"LA Bienvenu","year":"2012","unstructured":"Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM, Young MJ (2012) Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153(7):3416\u20133425. https:\/\/doi.org\/10.1210\/en.2011-2098","journal-title":"Endocrinology"},{"issue":"3","key":"10455_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","volume":"54","author":"AJ Rickard","year":"2009","unstructured":"Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54(3):537\u2013543. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.131110","journal-title":"Hypertension"},{"key":"10455_CR47","doi-asserted-by":"publisher","unstructured":"Young MJ, Kanki M, Karthigan N, Konstandopoulos P (2021) The role of the mineralocorticoid receptor and mineralocorticoid receptor-directed therapies in heart failure. Endocrinology 162(11) https:\/\/doi.org\/10.1210\/endocr\/bqab105","DOI":"10.1210\/endocr\/bqab105"},{"issue":"18","key":"10455_CR48","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE (2023) Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 81(18):1810\u20131834. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10455_CR49","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cardfail.2009.03.006","volume":"15","author":"AS Desai","year":"2009","unstructured":"Desai AS, Mitchell GF, Fang JC, Creager MA (2009) Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail 15(8):658\u2013664. https:\/\/doi.org\/10.1016\/j.cardfail.2009.03.006","journal-title":"J Card Fail"},{"issue":"3","key":"10455_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.hfc.2014.04.002","volume":"10","author":"A Kovacs","year":"2014","unstructured":"Kovacs A, Papp Z, Nagy L (2014) Causes and pathophysiology of heart failure with preserved ejection fraction. Heart Fail Clin 10(3):389\u2013398. https:\/\/doi.org\/10.1016\/j.hfc.2014.04.002","journal-title":"Heart Fail Clin"},{"issue":"4","key":"10455_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/jama.300.4.431","volume":"300","author":"SJ Shah","year":"2008","unstructured":"Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300(4):431\u2013433. https:\/\/doi.org\/10.1001\/jama.300.4.431","journal-title":"JAMA"},{"issue":"18","key":"10455_CR52","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","volume":"118","author":"AE Peters","year":"2023","unstructured":"Peters AE, Tromp J, Shah SJ, Lam CSP, Lewis GD, Borlaug BA, Sharma K, Pandey A, Sweitzer NK, Kitzman DW, Mentz RJ (2023) Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Cardiovasc Res 118(18):3403\u20133415. https:\/\/doi.org\/10.1093\/cvr\/cvac179","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10455_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131(3):269\u2013279. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010637","journal-title":"Circulation"},{"key":"10455_CR54","doi-asserted-by":"publisher","first-page":"607760","DOI":"10.3389\/fcvm.2020.607760","volume":"7","author":"D Harada","year":"2020","unstructured":"Harada D, Asanoi H, Noto T, Takagawa J (2020) Different pathophysiology and outcomes of heart failure with preserved ejection fraction stratified by K-means clustering. Front Cardiovasc Med 7:607760. https:\/\/doi.org\/10.3389\/fcvm.2020.607760","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10455_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/heartjnl-2019-315481","volume":"106","author":"AK Hedman","year":"2020","unstructured":"Hedman AK, Hage C, Sharma A, Brosnan MJ, Buckbinder L, Gan LM, Shah SJ, Linde CM, Donal E, Daubert JC, Malarstig A, Ziemek D, Lund L (2020) Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart 106(5):342\u2013349. https:\/\/doi.org\/10.1136\/heartjnl-2019-315481","journal-title":"Heart"},{"issue":"9","key":"10455_CR56","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ejhf.327","volume":"17","author":"DP Kao","year":"2015","unstructured":"Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J (2015) Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 17(9):925\u2013935. https:\/\/doi.org\/10.1002\/ejhf.327","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10455_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/1354750X.2020.1727015","volume":"25","author":"S Stienen","year":"2020","unstructured":"Stienen S, Ferreira JP, Kobayashi M, Preud\u2019homme G, Dobre D, Machu JL, Duarte K, Bresso E, Devignes MD, Lopez N, Girerd N, Aakhus S, Ambrosio G, Brunner-La Rocca HP, Fontes-Carvalho R, Fraser AG, van Heerebeek L, Heymans S, de Keulenaer G, Marino P, McDonald K, Mebazaa A, Papp Z, Raddino R, Tschope C, Paulus WJ, Zannad F, Rossignol P (2020) Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers 25(2):201\u2013211. https:\/\/doi.org\/10.1080\/1354750X.2020.1727015","journal-title":"Biomarkers"},{"issue":"3","key":"10455_CR58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Prenner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA (2020) Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail 8(3):172\u2013184. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.009","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10455_CR59","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.echo.2018.12.002","volume":"32","author":"M Przewlocka-Kosmala","year":"2019","unstructured":"Przewlocka-Kosmala M, Marwick TH, Dabrowski A, Kosmala W (2019) Contribution of cardiovascular reserve to prognostic categories of heart failure with preserved ejection fraction: a classification based on machine learning. J Am Soc Echocardiogr 32(5):604-615 e606. https:\/\/doi.org\/10.1016\/j.echo.2018.12.002","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"10455_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","volume":"143","author":"VS Hahn","year":"2021","unstructured":"Hahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, Stolina M, Yin J, Khakoo AY, Vaishnav J, Bader JS, Kass DA, Sharma K (2021) Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation 143(2):120\u2013134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050498","journal-title":"Circulation"},{"issue":"22","key":"10455_CR61","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1113\/JP281845","volume":"599","author":"E Jones","year":"2021","unstructured":"Jones E, Randall EB, Hummel SL, Cameron DM, Beard DA, Carlson BE (2021) Phenotyping heart failure using model-based analysis and physiology-informed machine learning. J Physiol 599(22):4991\u20135013. https:\/\/doi.org\/10.1113\/JP281845","journal-title":"J Physiol"},{"issue":"4","key":"10455_CR62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263\u2013271. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10455_CR63","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","volume":"128","author":"WJ Paulus","year":"2021","unstructured":"Paulus WJ, Zile MR (2021) From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res 128(10):1451\u20131467. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318159","journal-title":"Circ Res"},{"issue":"1","key":"10455_CR64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ejhf.1621","volume":"22","author":"MW Segar","year":"2020","unstructured":"Segar MW, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, Berry J, Grodin JL, Pandey A (2020) Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail 22(1):148\u2013158. https:\/\/doi.org\/10.1002\/ejhf.1621","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10455_CR65","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ejhf.2144","volume":"23","author":"RJ Woolley","year":"2021","unstructured":"Woolley RJ, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Metra M, Ng L, Samani N, van Veldhuisen DJ, Lang C, Lam CS, Voors AA (2021) Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail 23(6):983\u2013991. https:\/\/doi.org\/10.1002\/ejhf.2144","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10455_CR66","doi-asserted-by":"publisher","first-page":"e006414","DOI":"10.1161\/CIRCHEARTFAILURE.119.006414","volume":"13","author":"MS Sabbah","year":"2020","unstructured":"Sabbah MS, Fayyaz AU, de Denus S, Felker GM, Borlaug BA, Dasari S, Carter RE, Redfield MM (2020) Obese-inflammatory phenotypes in heart failure with preserved ejection fraction. Circ Heart Fail 13(8):e006414. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006414","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10455_CR67","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.echo.2019.08.002","volume":"32","author":"SJ Shah","year":"2019","unstructured":"Shah SJ (2019) 20th Annual Feigenbaum lecture: echocardiography for precision medicine-digital biopsy to deconstruct biology. J Am Soc Echocardiogr 32(11):1379-1395 e1372. https:\/\/doi.org\/10.1016\/j.echo.2019.08.002","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"10455_CR68","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","volume":"109","author":"TJ Wang","year":"2004","unstructured":"Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109(5):594\u2013600. https:\/\/doi.org\/10.1161\/01.CIR.0000112582.16683.EA","journal-title":"Circulation"},{"issue":"4","key":"10455_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","volume":"5","author":"IS Anand","year":"2017","unstructured":"Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O\u2019Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD (2017) Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail 5(4):241\u2013252. https:\/\/doi.org\/10.1016\/j.jchf.2016.11.015","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10455_CR70","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo DHFI (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781\u2013791. https:\/\/doi.org\/10.1001\/jama.2013.905","journal-title":"JAMA"},{"issue":"15","key":"10455_CR71","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"issue":"1","key":"10455_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O\u2019Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013255","journal-title":"Circulation"},{"issue":"4","key":"10455_CR73","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ehf2.13969","volume":"9","author":"M Choy","year":"2022","unstructured":"Choy M, Liang W, He J, Fu M, Dong Y, He X, Liu C (2022) Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ESC Heart Fail 9(4):2567\u20132575. https:\/\/doi.org\/10.1002\/ehf2.13969","journal-title":"ESC Heart Fail"},{"key":"10455_CR74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","volume":"146","author":"K Elkholey","year":"2021","unstructured":"Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S (2021) Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol 146:36\u201347. https:\/\/doi.org\/10.1016\/j.amjcard.2021.01.018","journal-title":"Am J Cardiol"},{"issue":"3","key":"10455_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","volume":"7","author":"M Merrill","year":"2019","unstructured":"Merrill M, Sweitzer NK, Lindenfeld J, Kao DP (2019) Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Fail 7(3):228\u2013238. https:\/\/doi.org\/10.1016\/j.jchf.2019.01.003","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10455_CR76","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O\u2019Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, Investigators T (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462. https:\/\/doi.org\/10.1093\/eurheartj\/ehv464","journal-title":"Eur Heart J"},{"issue":"6","key":"10455_CR77","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, Gonzalez A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F, Committees HT, Investigators, (2021) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 42(6):684\u2013696. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa758","journal-title":"Eur Heart J"},{"issue":"1","key":"10455_CR78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ejhf.2726","volume":"25","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur J Heart Fail 25(1):108\u2013113. https:\/\/doi.org\/10.1002\/ejhf.2726","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10455_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","volume":"1","author":"K Patel","year":"2013","unstructured":"Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A (2013) Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 1(1):40\u201347. https:\/\/doi.org\/10.1016\/j.jchf.2012.08.001","journal-title":"JACC Heart Fail"},{"issue":"17","key":"10455_CR80","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 79(17):1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10455_CR81","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 17(8):634\u2013642. https:\/\/doi.org\/10.1016\/j.cardfail.2011.04.007","journal-title":"J Card Fail"},{"issue":"8","key":"10455_CR82","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2012.05.049","volume":"110","author":"N Kampourides","year":"2012","unstructured":"Kampourides N, Tziakas D, Chalikias G, Papazoglou D, Maltezos E, Symeonides D, Konstantinides S (2012) Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. Am J Cardiol 110(8):1085\u20131091. https:\/\/doi.org\/10.1016\/j.amjcard.2012.05.049","journal-title":"Am J Cardiol"},{"key":"10455_CR83","unstructured":"Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT). In., \nhttps:\/\/clinicaltrials.gov.\u00a0(NCT02901184)"},{"key":"10455_CR84","unstructured":"Spironolactone in the treatment of heart failure (SPIRIT-HF). In., \nhttps:\/\/clinicaltrials.gov.\u00a0(NCT04727073)"},{"issue":"8","key":"10455_CR85","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","volume":"20","author":"KM Kurrelmeyer","year":"2014","unstructured":"Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A (2014) Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail 20(8):560\u2013568. https:\/\/doi.org\/10.1016\/j.cardfail.2014.05.010","journal-title":"J Card Fail"},{"issue":"5","key":"10455_CR86","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"P Kolkhof","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F (2015) Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 24(5):417\u2013424. https:\/\/doi.org\/10.1097\/MNH.0000000000000147","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10455_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B, Group B-CS (2021) Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension 78(1):74\u201381. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17073","journal-title":"Hypertension"},{"issue":"1","key":"10455_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S (2020) Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension 75(1):51\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13569","journal-title":"Hypertension"},{"issue":"6","key":"10455_CR89","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, Fidelio DKD, investigators F-D, (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"issue":"12","key":"10455_CR90","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, Sawanobori T (2020) Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 15(12):1715\u20131727. https:\/\/doi.org\/10.2215\/CJN.06870520","journal-title":"Clin J Am Soc Nephrol"},{"key":"10455_CR91","doi-asserted-by":"publisher","first-page":"1320603","DOI":"10.3389\/fendo.2023.1320603","volume":"14","author":"W Chen","year":"2023","unstructured":"Chen W, Zheng L, Wang J, Lin Y, Zhou T (2023) Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases. Front Endocrinol (Lausanne) 14:1320603. https:\/\/doi.org\/10.3389\/fendo.2023.1320603","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10455_CR92","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, Brix S, Betz IR, Schupp M, Foryst-Ludwig A, Klopfleisch R, Stawowy P, Houtman R, Kolkhof P, Kintscher U (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71(4):599\u2013608. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10360","journal-title":"Hypertension"},{"issue":"3","key":"10455_CR93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","volume":"135","author":"E Lerma","year":"2023","unstructured":"Lerma E, White WB, Bakris G (2023) Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med 135(3):224\u2013233. https:\/\/doi.org\/10.1080\/00325481.2022.2060598","journal-title":"Postgrad Med"},{"issue":"1","key":"10455_CR94","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, Eitner F, Albrecht-Kupper B, Schafer S (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64(1):69\u201378. https:\/\/doi.org\/10.1097\/FJC.0000000000000091","journal-title":"J Cardiovasc Pharmacol"},{"key":"10455_CR95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B (2017) Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol 243:271\u2013305. https:\/\/doi.org\/10.1007\/164_2016_76","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"10455_CR96","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux M, Barrera-Chimal J, Nicol L, Remy-Jouet I, Renet S, Dumesnil A, Wecker D, Richard V, Kolkhof P, Jaisser F, Ouvrard-Pascaud A, Mulder P (2018) Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab 20(10):2399\u20132407. https:\/\/doi.org\/10.1111\/dom.13393","journal-title":"Diabetes Obes Metab"},{"key":"10455_CR97","doi-asserted-by":"publisher","unstructured":"Lima-Posada I, Stephan Y, Soulie M, Palacios-Ramirez R, Bonnard B, Nicol L, Kolkhof P, Jaisser F, Mulder P (2023) Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction. Int J Mol Sci 24(3).\u00a0https:\/\/doi.org\/10.3390\/ijms24032536","DOI":"10.3390\/ijms24032536"},{"issue":"7","key":"10455_CR98","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","volume":"53","author":"K Luettges","year":"2022","unstructured":"Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U (2022) Finerenone reduces renal RORgammat gammadelta T cells and protects against cardiorenal damage. Am J Nephrol 53(7):552\u2013564. https:\/\/doi.org\/10.1159\/000524940","journal-title":"Am J Nephrol"},{"issue":"3","key":"10455_CR99","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/ehf2.13219","volume":"8","author":"M Pieronne-Deperrois","year":"2021","unstructured":"Pieronne-Deperrois M, Gueret A, Djerada Z, Crochemore C, Harouki N, Henry JP, Dumesnil A, Larcheveque M, Do Rego JC, Do Rego JL, Nicol L, Richard V, Jaisser F, Kolkhof P, Mulder P, Monteil C, Ouvrard-Pascaud A (2021) Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail 8(3):1933\u20131943. https:\/\/doi.org\/10.1002\/ehf2.13219","journal-title":"ESC Heart Fail"},{"issue":"40","key":"10455_CR100","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297\u20133317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641","journal-title":"Eur Heart J"},{"issue":"43","key":"10455_CR101","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1093\/eurheartj\/ehab389","volume":"42","author":"C Withaar","year":"2021","unstructured":"Withaar C, Lam CSP, Schiattarella GG, de Boer RA, Meems LMG (2021) Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. Eur Heart J 42(43):4420\u20134430. https:\/\/doi.org\/10.1093\/eurheartj\/ehab389","journal-title":"Eur Heart J"},{"key":"10455_CR102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P, Committees F-H, Investigators, (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"10455_CR103","unstructured":"A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF). In., \nhttps:\/\/clinicaltrials.gov.\u00a0(NCT06008197)"},{"issue":"1","key":"10455_CR104","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","volume":"9","author":"KS Jering","year":"2021","unstructured":"Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, Barkoudah E, McMurray JJV, Pfeffer MA, Solomon SD (2021) Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail 9(1):13\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.014","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10455_CR105","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ejhf.2722","volume":"24","author":"M Yang","year":"2022","unstructured":"Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, de Boer RA, Claggett BL, Desai AS, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Shah SJ, Vaduganathan M, Wilderang U, Solomon SD, McMurray JJV (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan. Eur J Heart Fail 24(12):2307\u20132319. https:\/\/doi.org\/10.1002\/ejhf.2722","journal-title":"Eur J Heart Fail"},{"issue":"37","key":"10455_CR106","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","volume":"44","author":"M Banerjee","year":"2023","unstructured":"Banerjee M, Maisnam I, Pal R, Mukhopadhyay S (2023) Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. Eur Heart J 44(37):3686\u20133696. https:\/\/doi.org\/10.1093\/eurheartj\/ehad522","journal-title":"Eur Heart J"},{"issue":"1","key":"10455_CR107","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL, Investigators F-D (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol 33(1):225\u2013237. https:\/\/doi.org\/10.1681\/ASN.2021070942","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10455_CR108","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","volume":"28","author":"J Malgie","year":"2023","unstructured":"Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ (2023) Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev 28(5):1221\u20131234. https:\/\/doi.org\/10.1007\/s10741-023-10325-2","journal-title":"Heart Fail Rev"},{"key":"10455_CR109","unstructured":"Study to evaluate the effect of balcinrenone\/dapagliflozin in patients with heart failure and impaired kidney function (BalanceD-HF). In., https:\/\/clinicaltrials.gov.\u00a0(NCT06307652)"},{"issue":"16","key":"10455_CR110","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z (2018) The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore) 97(16):e0254. https:\/\/doi.org\/10.1097\/MD.0000000000010254","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10455_CR111","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Hoft B, Klopfleisch R, Foryst-Ludwig A, Kolkhof P, Kintscher U (2016) Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol 67(5):402\u2013411. https:\/\/doi.org\/10.1097\/FJC.0000000000000366","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"10455_CR112","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao L, Mi Y, He W (2022) Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab 24(11):2159\u20132168. https:\/\/doi.org\/10.1111\/dom.14801","journal-title":"Diabetes Obes Metab"},{"key":"10455_CR113","doi-asserted-by":"publisher","first-page":"110161","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Morita R, Yamada T, Urate S, Azushima K, Uneda K, Kobayashi R, Kanaoka T, Wakui H, Tamura K (2022) Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Res Clin Pract 194:110161. https:\/\/doi.org\/10.1016\/j.diabres.2022.110161","journal-title":"Diabetes Res Clin Pract"},{"key":"10455_CR114","doi-asserted-by":"publisher","first-page":"110592","DOI":"10.1016\/j.diabres.2023.110592","volume":"198","author":"Q Yang","year":"2023","unstructured":"Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y, Xiao X, Qin C, Zou Y, Zhao Y, Kang D, Liu F (2023) Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110592. https:\/\/doi.org\/10.1016\/j.diabres.2023.110592","journal-title":"Diabetes Res Clin Pract"},{"key":"10455_CR115","doi-asserted-by":"publisher","unstructured":"Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H, Schroeder S, Schunkert H, Priori S, Esc Crt R, European Affairs Work Shop on Personalized M (2014) The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J 35(46):3250-3257.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehu312","DOI":"10.1093\/eurheartj\/ehu312"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10455-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:08:58Z","timestamp":1734160138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10455-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["10455"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10455-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"10 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the affiliation addresses of the authors.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}